Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARM 210

Next Previous
Drug Profile

ARM 210

Alternative Names: ARM-210; S-48168

Latest Information Update: 06 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARMGO Pharma
  • Developer ARMGO Pharma; National Institute of Neurological Disorders and Stroke; Servier
  • Class Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital structural myopathies; Polymorphic catecholergic ventricular tachycardia; Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Polymorphic catecholergic ventricular tachycardia
  • Phase I Congenital structural myopathies
  • No development reported Duchenne muscular dystrophy; Limb girdle muscular dystrophies; Sarcopenia; X-linked bulbo-spinal atrophy

Most Recent Events

  • 29 Jan 2024 Efficacy data from a phase I trial in Congenital structural myopathies released by ARMGO Pharma
  • 29 Jan 2024 ARMGO Pharma plans a phase II trial for Congenital structural myopathies
  • 29 Jan 2024 Armgo Pharma completes a phase I trial in Congenital structural myopathies in USA (PO) (NCT04141670)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top